Fiche publication
Date publication
septembre 2018
Journal
Radiation oncology (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie
Tous les auteurs :
Zilli T, Scorsetti M, Zwahlen D, Franzese C, Förster R, Giaj-Levra N, Koustouvelis N, Bertaut A, Zimmermann M, D'Agostino GR, Alongi F, Guckenberger M, Miralbell R
Lien Pubmed
Résumé
Stereotactic body radiotherapy (SBRT) is an emerging treatment alternative for patients with localized prostate cancer. Promising results in terms of disease control and toxicity have been reported with 4 to 5 SBRT fractions. However, question of how far can the number of fractions with SBRT be reduced is a challenging research matter. As already explored by some authors in the context of brachytherapy, monotherapy appears to be feasible with an acceptable toxicity profile and a promising outcome. The aim of this multicenter phase I/II prospective trialis to demonstrate early evidence of safety and efficacy of a single-fraction SBRT approach for the treatment of localized disease.
Mots clés
Electromagnetic transponders, Prostate cancer, Quality of life, Single fraction, Stereotactic body radiotherapy, Urethra-sparing
Référence
Radiat Oncol. 2018 Sep 4;13(1):166
